% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • riskreturn168 riskreturn168 Jul 2, 2014 10:41 AM Flag

    AMBS Business Model

    AMBS' Business Model for MANF is to look for promising indications that can receive orphan designation, reducing the time and money needed to obtain final FDA approval. This makes the indication desirable for partnerships. As of today, RP seems to be ahead of Wolframs in getting orphan designation, but possibly not by much. Both RP and Wolframs have data coming out in prominent Journals this month. RP is likely to obtain orphan designation by this fall, and possibly wolframs too. Dr. Urana said this week that they are in talks with a Big Pharma regarding a partnership. That is AMBS' goal for both of these indications: a partnership this year with up front cash and milestone payments for future progress. Perhaps we get one partnership before up listing and the other partnership soon after up listing? These are nice catalysts for the stock price, in addition to the huge impact LymPro is going to have on our price in the coming weeks and months. Gerald was also seeking orphan status for Eltoprazine as well. Once Eltoprazine's trial gets firmed up I expect some grant from MJFF to help with funding. Gerald also indicated we would be hearing about more MANF indications, adding to the pipeline.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.0459+0.0054(+13.33%)11:44 AMEDT